echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Risk of microbial contamination Mercedon recalls 6 batches of sterile drugs

    Risk of microbial contamination Mercedon recalls 6 batches of sterile drugs

    • Last Update: 2020-12-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Mercadon recalled its compound antibiotic product Zerbaxa because of microbial contamination, involving multiple batches, and Fessenyuskabi recalled 0.9 percent sodium chloride injections because some products were labeled Polish.
    recall: Sterile drugs are at risk of microbial contamination Merck Sharp and Dohme Limited is recalling its compound antibiotic product Zerbaxa.
    recall involves specific batches of Zerbaxa infusion concentrate powders in sizes of 1g / 0.5g.
    : Recalled product: compound antibiotic Zerbaxa.
    the most active ingredient is ceftolozane sulfate / tazobactam sodium, the active ingredient is the recall of the above batch because of the presence of Ralstonia pickettii contamination in recently produced batches.
    this deviation, Mercedon initiates further investigations into the microbial quality of distributed products.
    as a precautionary measure, Mercedon decided to recall the following commercially available batches: Figure: List of Recalled Product Batches Meshadon said the likelihood of contamination occurring in those batches was low.
    even if these batches were present, the level of contamination would not be high and could lead to serious adverse health consequences.
    is a Terrain-negative bacteria found in soil, rivers and lakes.
    in water systems containing industrial plastics, they can be found in the form of biofilm bacteria.
    to medical professionals to stop supplying the above batches immediately.
    all inventory and return it to the supplier using a supplier-approved process.
    patients with worsening symptoms or other suspected side effects during treatment with Zerbaxa should be reported through the Yellow Card Program (UK Adverse Reaction Reporting System).
    , Fessenyuscabi: Labeling language error Fresenius Kabi Ltd is recalling 0.9 percent sodium chloride injections.
    the ampoules in some small boxes are labeled Polish, and while this will not affect the entire batch, Fessenyuscabi decided to recall all packages in this batch as a precaution.
    : Warning Notices from the UK's drug regulator, Fessen Yuscabi, says the small boxes in the batch are correct and have the correct instructions (in English).
    drug ingredients and specifications meet UK licensing requirements, the batch used the wrong version of the ampoule label in the production process.
    Faison Yuscabi decided to recall the following batches affected, and all returns will be replaced with other inventory batches.
    image: Recall product batch information
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.